Here, we extend our previous in vitro studies to an ex vivo model in order to demonstrate that systemic candidiasis or TLR2 agonist exposure in vivo impacts the antifungal phenotype of the macrophages produced in vitro from purified HSPCs. The gene discussed is TLR2; the disease is candidiasis.